Immune checkpoint inhibitors (ICIs) significantly improve survival in lung cancer patients.
However, checkpoint inhibitor pneumonitis (CIP) remains a critical safety concern.
This meta-analysis systematically evaluates demographic, clinical, and laboratory risk factors associated with CIP development to guide risk-stratified management.
